Literature DB >> 11069441

Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.

S J Porter1, A A Somogyi, J M White.   

Abstract

AIMS: To determine the kinetics of the formation of 6beta-naltrexol from naltrexone in human liver cytosol, and to investigate the role of potential inhibitors.
METHODS: The kinetics of the formation of 6 beta-naltrexol from naltrexone were examined in eight human liver cytosol preparations using h.p.l.c. to quantify 6 beta-naltrexol and, the extent of inhibition of 6 beta-naltrexol formation was determined using chemical inhibitors. The formation of 6 beta-naltrexol and the back reaction of 6 beta-naltrexol to naltrexone were also examined in a microsomal preparation.
RESULTS: The Vmax, Km and CLint values for the formation of 6 beta-naltrexol from naltrexone were in the ranges of 16-45 nmol mg-1 protein h-1, 17-53 microM and 0.3-2.2 ml h-1 mg-1 protein, respectively. The steroid hormones testosterone (Ki = 0.3 +/- 0.1 microM) and dihydrotestosterone (Ki = 0.7 +/- 0.4 microM) were the most potent competitive inhibitors of 6 beta-naltrexol formation, with naloxone, menadione and corticosterone also producing > 50% inhibition at a concentration of 100 microM. The opioid agonists morphine, oxycodone, oxymorphone and hydromorphone, and a range of benzodiazepines showed < 20% inhibition at 100 microM. In the microsomal preparation, there was no formation of naltrexone from 6beta-naltrexol nor any formation of 6beta-naltrexol from naltrexone.
CONCLUSIONS: The intersubject variability in the kinetic parameters of 6beta-naltrexol formation could play a role in the efficacy of and patient compliance with naltrexone treatment. This variability could be due in part to a genetic polymorphism of the dihydrodiol dehydrogenase DD4, one of the enzymes reported to be responsible for the formation of 6beta-naltrexol from naltrexone. DD4 also has hydroxysteroid dehydrogenase activity which could account for the potent inhibition by the steroid hormones testosterone and dihydrotestosterone. The clinical significance of the latter finding remains to be established.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069441      PMCID: PMC2014407          DOI: 10.1046/j.1365-2125.2000.00281.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Stereospecific synthesis of the 6beta-hydroxy metabolites of naltrexone and naloxone.

Authors:  N Chatterjie; C E Inturrisi
Journal:  J Med Chem       Date:  1975-05       Impact factor: 7.446

2.  Characterization of a novel variant (S145C/L311V) of 3alpha-hydroxysteroid/dihydrodiol dehydrogenase in human liver.

Authors:  T Kume; H Iwasa; H Shiraishi; T Yokoi; K Nagashima; M Otsuka; T Terada; T Takagi; A Hara; T Kamataki
Journal:  Pharmacogenetics       Date:  1999-12

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat.

Authors:  H E Dayton; C E Inturrisi
Journal:  Drug Metab Dispos       Date:  1976 Sep-Oct       Impact factor: 3.922

5.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.

Authors:  U M Zanger; F Vilbois; J P Hardwick; U A Meyer
Journal:  Biochemistry       Date:  1988-07-26       Impact factor: 3.162

6.  Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.

Authors:  K Verebey; J Volavka; S J Mulé; R B Resnick
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

7.  Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.

Authors:  M C Meyer; A B Straughn; M W Lo; W L Schary; C C Whitney
Journal:  J Clin Psychiatry       Date:  1984-09       Impact factor: 4.384

8.  Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase.

Authors:  B Wermuth
Journal:  J Biol Chem       Date:  1981-02-10       Impact factor: 5.157

9.  Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein.

Authors:  B Wermuth; K M Bohren; G Heinemann; J P von Wartburg; K H Gabbay
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

10.  Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes.

Authors:  E R Korpi; D T Costakos; R J Wyatt
Journal:  Biochem Pharmacol       Date:  1985-08-15       Impact factor: 5.858

View more
  5 in total

1.  Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

Authors:  Pallabi Mitra; Jürgen Venitz; Yunyun Yuan; Yan Zhang; Phillip M Gerk
Journal:  Drug Metab Dispos       Date:  2011-06-17       Impact factor: 3.922

2.  Effects of Naltrexone on Expression of Lipid Metabolism-Related Proteins in Liver Steatosis Induced by Endoplasmic Reticulum Stress in Mice.

Authors:  Ping Yang; Leyao Xiao; Fei Zhao; Wei He; Guijuan Zhang; Yongjing Tang; Yinghua Chen; Qijiao Cheng; Yihuai He
Journal:  Contrast Media Mol Imaging       Date:  2022-05-29       Impact factor: 3.009

Review 3.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

Review 4.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 5.  Improving clinical outcomes for naltrexone as a management of problem alcohol use.

Authors:  Gary K Hulse
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.